Strategic partnerships Leverage NeuraLight’s existing collaborations with CHDI Foundation, Kariya pharma, and ongoing neurodegenerative focused programs to position joint biomarkers-enabled trials as a premium service. Target mid-sized pharma and biotech firms seeking objective, scalable brain function endpoints for Huntington's disease, Parkinson's disease, and related conditions.

Clinical endoints Position NeuraLight as a provider of precision brain biomarkers that can serve as sensitive endpoints in clinical trials. Develop tailored outreach to CROs and trial sponsors looking to enhance trial accuracy and reduce time to proof-of-mechanism, focusing on GLP-1 related neuroprotection programs and neurodegenerative indications.

Expansion readiness Capitalize on leadership changes and Copenhagen presence to establish regional partnerships in Europe, offering bilateral collaboration opportunities, data-sharing pilots, and co-development of measurement tools that align with European regulatory expectations for neurodegenerative trials.

Market validation Highlight recognition as a finalist for Prix Galien USA and endorsements by neurologists and Nobel laureates to build credibility with potential customers. Use these milestones in outreach to investors, CROs, and pharma decision-makers to accelerate pilot programs.

Scale through trials Target mid-market biopharma and biotech players with ongoing CNS programs and limited internal biomarker capabilities. Offer a scalable, validated measurement platform that integrates with existing data ecosystems (cloud, AI engines) to enable faster, more reliable neuro endpoints and trial analytics.